Sequenom announces genetics discovery collaboration with Bristol-Myers Squibb
"Bristol-Myers Squibb is making significant progress in developing novel drug targets and we are proud to form this strategic relationship," said Toni Schuh, Ph.D., Sequenom's President and Chief Executive Officer. "This collaboration serves as an excellent example of the broad application of Sequenom's strategy to elucidate disease-related genes and genetic variations. This is an exciting opportunity to utilize our genetics discovery expertise with targets identified by Bristol-Myers Squibb in an effort to develop novel diagnostic and therapeutic products."
"We look forward to our collaborative efforts with Sequenom," said Nicholas C. Dracopoli, Ph.D., Vice President, Clinical Discovery Technologies at Bristol-Myers Squibb Pharmaceutical Research Institute. "This is an exciting opportunity to use Sequenom's genotyping platform and unique collection of DNA samples to screen a large set of our novel, early-stage drug targets for their role in a wide range of therapeutic areas."
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.